Direct Healthcare Professional Communication on potential risks of cardiovascular and renal adverse events in patients with type 2 diabetes and renal impairment and/or cardiovascular disease treated with aliskiren

Novartis would like to update healthcare professionals about important new safety information for aliskiren (Rasilez®) following the early termination of the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE). Analyses of these data are ongoing. In the meantime as a precautionary measure, routine (non-urgent) review is recommended for patients taking aliskiren-containing medicines. Aliskiren or aliskiren-containing fixed combination products should not be used in combination with angiotensin  converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) in patients with diabetes. Healthcare professionals are advised to stop aliskiren-containing treatment in patients who are diabetic and also taking an ACE inhibitor or an ARB. Alternative antihypertensive treatment should be considered as necessary. Aliskiren-containing products should not be initiated in diabetic patients who are also taking either an ACE inhibitor or ARB. Patients should be advised not to stop any treatment before discussing with a healthcare professional.

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of these letters can be found in the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://hpp.moh.gov.sg ↗ (opens in new tab) and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under ‘For Healthcare Professionals’.

Step 2: Click on ‘Useful links’.

Step 3: Click on ‘MOH Alert’ and log in via Singpass.

Step 4: Click on ‘Drug Alerts’ or ‘Med Device Alerts’ to view the DHCPLs.